2025-12-31 - Analysis Report
Here's an analysis of Procter & Gamble (PG) based on the provided data:

**1) Return Rate Comparison:**

*   **Company Overview:** Procter & Gamble Co. is a multinational consumer goods corporation focusing on a wide range of branded products.
*   **PG Cumulative Return:** 25.78%
*   **VOO (S&P 500) Cumulative Return:** 102.21%
*   **Divergence:** -76.8 (Relative Divergence: 3.4)

**Analysis:** PG has significantly underperformed the S&P 500 (VOO) over the period for which cumulative return data is available. The divergence of -76.8 indicates a substantial performance gap. The relative divergence of 3.4 suggests that the current performance gap is near the bottom of its historical range compared to VOO.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD   | Alpha  | Beta | Cap(B) |
|------------|---------|-------|--------|------|--------|
| 2015-2017  | 21.0%   | 7.9%  | -8.0%  | 0.0  | 215.0  |
| 2016-2018  | 9.0%    | 67.3% | -6.0%  | 0.1  | 215.1  |
| 2017-2019  | 24.0%   | 70.4% | 2.0%   | 0.3  | 292.3  |
| 2018-2020  | 27.0%   | 78.8% | 4.0%   | 0.4  | 325.7  |
| 2019-2021  | 41.0%   | 78.8% | -5.0%  | 0.5  | 382.9  |
| 2020-2022  | 13.0%   | 79.4% | 13.0%  | 0.6  | 354.7  |
| 2021-2023  | 26.0%   | 79.4% | 24.0%  | 0.4  | 343.0  |
| 2022-2024  | 9.0%    | 79.4% | -12.0% | 0.4  | 392.4  |
| 2023-2025  | -18.0%  | 80.1% | -85.0% | 0.1  | 337.1  |

**Analysis:**

*   **CAGR:** Varies significantly. The most recent period (2023-2025) shows a negative CAGR of -18.0%.
*   **MDD:** Maximum Drawdown has been quite high, particularly in recent periods, reaching over 70%. This suggests that the stock has experienced substantial declines from peak values.
*   **Alpha:** Alpha fluctuates.  The negative alpha in the most recent period (-85.0%) is very concerning, indicating significant underperformance relative to its benchmark. Alpha in previous years are positive, but still low in comparison.
*   **Beta:** Beta values are generally low (between 0.0 and 0.6), indicating that PG's price movements are less volatile than the overall market.
*   **Cap(B):** Company capitalization has varied throughout these periods.

**2) Recent Stock Price Fluctuations:**

*   **Current Close:** 144.05
*   **Previous Close:** 144.57
*   **Change:** -0.36
*   **5-day SMA:** 144.21
*   **20-day SMA:** 143.67
*   **60-day SMA:** 147.17

**Analysis:** The stock price is slightly down in the most recent trading day. The 5-day SMA is above the 20-day SMA, indicating a possible short-term upward trend. However, the 60-day SMA is higher than both, suggesting that the longer-term trend is still downward or sideways.

**3) Indicators:**

*   **MRI:** 0.9 (High Investment Recommended)
*   **RSI:** 63.78 (Neutral to slightly overbought)
*   **PPO:** 0.19 (Positive, but low)
*   **Hybrid Signal:**  cash_0%_Buy 100% of cash (7 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent Relative Divergence Change:** -4.6 (Short-term decline)
*   **Expected Return (%):** -8.1 (Negative expected return compared to S&P 500)

**Analysis:**

*   The Market Risk Indicator (MRI) suggests a high investment recommendation, potentially conflicting with the stock's underperformance and negative expected return.
*   The RSI is around 64, indicating neither overbought nor oversold conditions.
*   PPO is slightly positive.
*   The hybrid signal recommends buying P&G, but this contradicts other negative data.
*   The negative change in relative divergence suggests a recent short-term decline in performance relative to the S&P 500.
*   The negative expected return indicates that, based on current conditions, long-term investment in PG might underperform the S&P 500.

**4) Recent News & Significant Events:**

*   **Mixed Analyst Sentiment:** News headlines include both positive (Jim Cramer's comments) and negative (price decline) viewpoints.
*   **Earnings Concerns:** Articles mention opinions on recent earnings and a price decline following the Q1 FY26 report.
*   **Institutional Holdings:** Information about Fort Washington Investment Advisors' stake provides insight into institutional investor activity.

**Analysis:** The news highlights a mixed outlook for PG. While some analysts express optimism, concerns about earnings and recent price declines are also present.

**4-2) Analyst Opinions:**

*   **Consensus:** Buy
*   **Mean Rating:** 1.92 (leaning towards "Buy")
*   **Target Price:** Average target of $168.95, with a range of $148.00 to $186.00.

**Analysis:** Analyst consensus remains positive, with a "Buy" rating and a target price significantly above the current price. This suggests analysts believe the stock is undervalued.

**5) Recent Earnings Analysis:**

| 날짜       | EPS  | 매출       |
|------------|------|------------|
| 2025-10-24 | 2    | 22.39 B$   |
| 2025-04-24 | 1.58 | 19.78 B$   |
| 2025-01-22 | 1.94 | 21.88 B$   |
| 2024-10-18 | 1.65 | 21.74 B$   |
| 2025-10-24 | 1.65 | 21.74 B$   |

**Analysis:** The earnings data shows fluctuating EPS and revenue. Revenue experienced an overall increase from Q4 2024 to Q4 2025, and so did EPS.

**6) Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | $22.39B   | 51.37%        |
| 2025-06-30   | $20.89B   | 49.11%        |
| 2025-03-31   | $19.78B   | 50.98%        |
| 2024-12-31   | $21.88B   | 52.39%        |
| 2024-09-30   | $21.74B   | 52.06%        |

**Analysis:** Revenue and Profit Margin have fluctuated. Revenue generally showed positive growth and profit margin showed some volatility.

**Capital and Profitability:**

| Quarter      | Equity    | ROE   |
|--------------|-----------|-------|
| 2025-09-30   | $53.27B   | 8.92% |
| 2025-06-30   | $52.01B   | 6.95% |
| 2025-03-31   | $52.27B   | 7.21% |
| 2024-12-31   | $51.17B   | 9.05% |
| 2024-09-30   | $51.84B   | 7.64% |

**Analysis:** Equity has been generally increasing. ROE has shown some fluctuations.

**7) Comprehensive Analysis:**

**Summary:**

The analysis paints a mixed picture for Procter & Gamble. While the company is a large, established player with a history of strong performance, recent data suggests challenges.

*   **Underperformance:** PG has significantly underperformed the S&P 500, with a substantial negative divergence.
*   **Mixed Indicators:** The MRI suggests a high investment recommendation, but the negative expected return and negative change in relative divergence raise concerns.
*   **Analyst Optimism vs. Recent Performance:**  Analysts maintain a "Buy" rating and target price significantly above the current level, suggesting they believe the stock is undervalued. However, this contrasts with the recent underperformance, negative expected return, and the company's negative alpha.
*   **Recent Earnings and Profitability:** Revenue experienced an overall increase from Q4 2024 to Q4 2025, and so did EPS. Equity has been generally increasing. ROE has shown some fluctuations.
*   **Capital and Profitability:** Recent high Maximum Drawdown, suggest that the stock has experienced substantial declines from peak values.

**Investment Recommendation:**

The investment decision is complex. While analysts are bullish, the recent underperformance, negative expected return, and negative alpha present a cautionary tale. The MRI recommendation is contradicted by other indicators.

*   **Considerations:**
    *   **Value Play:** The analyst's "Buy" rating suggests the stock may be undervalued, offering potential for future gains.
    *   **Risk Tolerance:** The negative expected return means there is potential that returns will be below the overall market for a long period of time.
    *   **Diversification:** P&G's low beta can offer stability in a portfolio.
*   **Recommendation:** A cautious approach is warranted. Given the negative expected return and recent underperformance, investors should carefully weigh the risks before investing. A smaller allocation might be suitable for those seeking diversification and potential value. Investors looking for growth may want to look elsewhere. The divergence between analyst sentiment and actual performance data raises a key point to consider. A hold, or small buy position is appropriate while waiting for more data.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.